Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

NCT05225259 | Unknown

• 1 other identifier: LOXO-260 Expanded Access
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor. The treating physician/investigator contacts Loxo Oncology, Inc. when, based on their medical opinion, a patient meets the criteria for expanded access.

Conditions

Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms

Keywords

Solid tumors

Interventions

LOXO-260 DRUG

Oral

Also known as: LY3838915

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of cancer with RET mutant (medullary thyroid cancer \[MTC\] or multiple endocrine neoplasia type 2 \[MEN2\] tumors) or RET fusion (solid tumors) advanced/metastatic tumors that have become refractory to RET selective tyrosine kinase inhibitor (TKI) treatment, who are not eligible or able to participate in an ongoing LOXO-260 clinical trial and are medically suitable for treatment with LOXO-260.
• Patients tumor must have developed RET solvent front mutations (eg G810X) after RET selective treatment.
• Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
• Have adequate organ function
• Patients must reside in a country where the LOXO-NGR-21001 study (NCT05241834) is not open or recruiting.

You may not qualify if:

• Currently enrolled in an ongoing clinical study of LOXO-260 or another second generation RET inhibitor
• Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
• Clinically significant malabsorption syndrome
• Pregnant or lactating
• Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4
• Patients harboring known activating bypass alterations outside RET (eg. EGFR, ALK, RAS etc) that may confer resistance to LOXO-260

Sponsors & Collaborators

• Eli Lilly and Company: lead
• Loxo Oncology, Inc.: collaborator

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Study Officials

• Emin Avsar, MD

  Loxo Oncology, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 28, 2022
• First Posted: February 4, 2022
• Last Updated: February 28, 2024

Record last verified: 2024-02